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Abstract
Hypoxia has been long-time acknowledged as major cancer-promoting microenvironment. In such an energy-
restrictive condition, post-transcriptional mechanisms gain importance over the energy-expensive gene transcription
machinery. Here we show that the onset of hypoxia-induced cancer stem cell features requires the beta-catenin-
dependent post-transcriptional up-regulation of CA9 and SNAI2 gene expression. In response to hypoxia, beta-
catenin moves from the plasma membrane to the cytoplasm where it binds and stabilizes SNAI2 and CA9 mRNAs, in
cooperation with the mRNA stabilizing protein HuR. We also provide evidence that the post-transcriptional activity of
cytoplasmic beta-catenin operates under normoxia in basal-like/triple-negative breast cancer cells, where the beta-
catenin knockdown suppresses the stem cell phenotype in vitro and tumor growth in vivo. In such cells, we unravel
the generalized involvement of the beta-catenin-driven machinery in the stabilization of EGF-induced mRNAs,
including the cancer stem cell regulator IL6. Our study highlights the crucial role of post-transcriptional mechanisms
in the maintenance/acquisition of cancer stem cell features and suggests that the hindrance of cytoplasmic beta-
catenin function may represent an unprecedented strategy for targeting breast cancer stem/basal-like cells.
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Introduction
Stem cells are harbored in specialized niches where low
oxygen tension (hypoxia) contributes to the regulation of self-
renewal and differentiation [1–3]. In fact, hypoxia maintains the
undifferentiated state of embryonic, hematopoietic,
mesenchymal and neural stem/progenitor cells [2]. Hypoxia in
tumors is associated with poor prognosis [4]. Cells in hypoxic
tumor regions stabilize hypoxia-inducible-factors (HIFs) and
activate adaptive gene expression leading to cancer
aggressiveness through cell survival and dedifferentiation [1,5].
Moreover, HIF activity in a rare subset of hypoxic tumor cells
confers stem cell-like properties [1–3].
Beta-catenin is a crucial regulator of normal and cancer stem
cell self-renewal [6,7]. In response to various stimuli, beta-
catenin induces the expression of target genes by shuttling into
the nucleus, where it interacts with TCF/LEF family
transcription factors [6].
Physical interaction between HIF-1alpha, the major player in
hypoxia response, and beta-catenin has been described [8].
Moreover, beta-catenin and HIF-1alpha synergistically facilitate
hypoxia survival in colon cancer cells and self-renewal in
neural stem cells [8,9].
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Hypoxia is an energy restrictive condition, which markedly
decreases total de novo transcription and promotes the energy-
saving post-transcriptional regulation of pre-existing mRNAs
[10–12]. Recent studies report that beta-catenin modulates the
half-life of cytoplasmic mRNAs [13–17]. These data lead to us
surmise that the post-transcriptional activity of beta-catenin
plays an important role in the adaptation of cancer cells to
hypoxia. Here we analyzed the role of beta-catenin in the
mRNAs production and stabilization of two important breast
cancer stem cell regulatory genes, i.e. carbonic anhydrase 9
(CA9) and SNAI2. The expression of CA9 and SNAI2 genes is
induced by hypoxia, via HIF1-alpha-mediated transcriptional
up-regulation [18–20]. CA9 expression regulates pH in the
hypoxic microenvironment to promote survival and proliferation
of cancer stem cells [21,22]. Therefore CA9 has been
suggested as an anticancer therapy target [23,24]. SNAI2, also
known as SLUG, is an important functional suppressor of
human breast progenitor cell lineage commitment and
differentiation, promoting normal and tumor mammary gland
stem/progenitor cells state [25,26].
We here report that the cytoplasmic accumulation of beta-
catenin in response to hypoxia activates a post-transcriptional
de-differentiation and survival program, which enhances stem
cell features in breast cancer cells. The phenomenon relies
upon the ability of cytoplasmic beta-catenin to bind and
stabilize SNAI2 and CA9 mRNAs. We also provide evidence
that the post-transcriptional activity of cytoplasmic beta-catenin
operates under normoxia in basal-like/triple-negative breast
cancer cells. The basal-like/triple-negative breast cancer is a
poorly differentiated and aggressive breast cancer subtype,
characterized by the expression of a stem cell-like gene profile
[27,28], by the cytoplasmic localization of beta-catenin [29–31]
and by CA9 and SNAI2 gene overexpression [32,33]. In such
cells, beta-catenin knockdown dramatically diminished the
stability and expression of CA9 and SNAI2 mRNAs and blunts
the stem cell phenotype in vitro and the xenograft-establishing
capability in vivo. Moreover, beta-catenin beta-catenin was
able to regulate the mRNA stability of several EGF-induced
mRNAs, among which the pro-inflammatory cytokine
Interleukin 6 (IL6), an acknowledged cancer stem growth factor
[21,34]. The data here reported highlight the role of post-
transcriptional mechanisms in the regulation of cancer stem
cell features, and identify beta-catenin as a pivotal post-
transcriptional player in the breast cancer stem cell phenotype.
We propose that the hindrance of beta-catenin post-
transcriptional activity here described represents a not yet
explored strategy to target breast cancer stem/basal-like cells.
Materials and Methods
Cell lines, chemicals and hypoxia exposure
We used MCF7 cells as a model of well-differentiated luminal
breast carcinoma and MDA-MB-468 and MDA-MB-231 cells as
a model of poorly differentiated basal-like breast carcinoma
[35]. All the cell lines were purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA). MCF7, MDA-
MB-468 and MDA-MB-231 were grown in RPMI-1640,
DMEM/F12 and DMEM respectively. All media were
supplemented with 10% FBS, 1% of penicillin and streptomycin
and 1% of glutamine Euroclone (Milan-Italy). All the normoxic
cell cultures were kept at 37°C in a 5% CO2-humidified
atmosphere. Hypoxia (1%pO2, 5%pCO2, 94%pN2) was
obtained in an invivo300 hypoxia cabinet (Ruskinn Technology,
Bridgend, UK) for 48 h. Cell death was evaluated by Trypan
blue staining.
Generation of MS from primary breast cancer tissues
and cell lines
MS from human mammary gland tissues were obtained as
previously described [21]. Briefly, tissue specimens were
placed in sterile Epicult media (StemCell Technologies,
Vancouver, Canada), minced with sterile scalpels, and
incubated for 6–12 hours in presence of 1,000 U Collagenase/
Hyaluronidase enzyme mix (StemCell Technologies) and
filtered through a 40 μm nylon mesh (Becton Dickinson), re-
suspended in complete MEGM and plated into 1cm2 low
attachment plates. Secondary MS generation was obtained by
incubating primary or consecutive MS in 1× Trypsin-EDTA
solution (Cambrex) for 3 minutes, filtration throughout a 40-μm
nylon mesh and single cell re-suspension in complete MEGM.
MS were scored at day 7. Clearance was obtained from the
S.Orsola-Malpighi Hospital ethical committee, University of
Bologna (Prot. n. 75/2011 to LM and MB and MT). Written
informed consent was obtained from patients whose tissues
were used in the study. MCF7-MS were generated by seeding
5000 MCF7 cells in low attachment 24 well and scored at day
5.
Stable Beta-catenin and SNAI2 knockdown in MCF7,
MDA-MB-468 and MDA-MB-231 cells
Stable beta-catenin knockdown in MCF7, MDA-MB-468 and
MDA-MB-231 cells was achieved by transducing the
pCtoGMB-GFP retroviral vector carrying human beta-catenin
specific 19nt coding sequence (GAGCCTCTATACCACCCAC)
by a PCR-based cloning strategy, as previously described for
shSNAI2 vector [20]. shBeta and shSNAI2-infected cells were
selected by GFP cytofluorimetric sorting, as previously
described [20].
Immunofluorescence and Confocal microscopy
analysis
Cultured cells were seeded onto glass coverslips at 60%
confluence, while MS were cultured in BD reduced MatrigelTM
(Becton Dickinson, Franklin Lakes, NJ). Cells were fixed with
2% paraformaldehyde and permeabilized with 0.2% Triton
X-100. Cells were incubated with anti-beta-catenin primary
antibody (clone E5, Santa Cruz Biotechnologies, Santa Cruz,
CA) and secondary anti-mouse FITC conjugated antibody
(Dako Cytomation, Glostrup, DK). Nuclei were counter-stained
with propidium iodide and mounted in the anti-fade Pro-long
reagent mounting medium (Molecular Probes Inc, Eugene,
Oregon, USA). Images were captured using a Zeiss LSM 710
on a Zeiss Observer Z1 or a Leica DMI 6000B inverted
microscope (Leica Microsystems GmbH, Wetzlar, Germany).
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Transient transfection of siRNA and expression vectors
CA9-, HuR-, and SNAI2-specific siRNAs and non-specific
siRNA control (siSCR) oligonucleotides (StealthTM technology)
with a matched GC content were purchased from Invitrogen
(Carlsbad, CA, USA). Plasmids encoding wild type beta-
catenin (Beta-WT; pCI-neo), dominant negative pcDNA4-
TCF4DN (TCF4DN), and pTER+shBeta-catenin (shBeta)
encoding vector were obtained from Dr. Marc Van De Wetering
(Hubrecht Institute, Utrecht, Netherlands) and Bert Vogelstein
(Johns Hopkins University, MD, USA). Plasmid encoding HIF1-
alpha was obtained from Eric Huang (Department of
Neurosurgery, University of Utah, Salt Lake City, Utah). Wild
type EGFR encoding vector was obtained from Pier Paolo di
Fiore (European Institute of Oncology, Milan, Italy); siRNAs or
plasmids were transfected to MCF7 cells (105 cells in a 3 cm2
well) at a concentration of 1 µg/well for 72h or 24 h respectively
using lipofectamine 2000 (Life Technologies, Gran Island, NY),
or Jet-Pei (Polyplus, Illkirch, France) in the case of MS. MCF7
cells stably transduced with a retroviral vector encoding a p53
dominant inactivating mini-protein (p53D) were previously
described [36].
Gene promoter and mRNA 3’UTR luciferase reporter
assays
Carbonic anhydrase-9 luciferase plasmid (CA9-Luc,
spanning the -170 to +34 region of CA9 promoter), was kindly
provided by Dott. Jaromir Pastorek; HIF1alpha responding
luciferase plasmid, HRE-Luc, was kindly provided by Dr.
Giovanni Melillo (Tumor hypoxia laboratory, National Cancer
Institute, Frederick, MD, USA). SNAI2-Luc plasmid was kindly
provided by Dr. Togo Ikuta (Saitama Cancer Centre, Saitama,
Japan); TopFlash, was a gift of Dr. Rolf Kemler (Max Planck
Institute, Heidelberg, Germany); Estrogen Response Element
(ERE-Luc) reporter was provided by Rakesh Kumar
(Department of Molecular and Cellular Oncology, MD Anderson
Cancer Center, Houston, Texas); Thymidine Kinase Renilla
luciferase reporter plasmid (Promega, Madison, WI) was used
as control in luciferase assay after 24 hours using the Dual-
Luciferase® Reporter Assay System (Promega), according to
the manufacturer’s instructions. Data are expressed as fold
changes of firefly over renilla luciferase activity. CA9 and
SNAI2 3’UTR luciferase assay constructs were obtained from
Genecopoeia (Rockwell, Maryland, USA). Each cell line was
transfected with 3’UTR-CA9/SNAI2 vector or with control
pEZX-MT01 empty vector. Data are presented as ratio of
3’UTR-CA9/SNAI2 over control vector, according to
manufacturer instructions.
RNA extraction and cDNA amplification
Total RNA was extracted from cells using TRIzol® Reagent
according to the manufacturer’s protocol (Invitrogen, Carlsbad,
CA). Primers and PCR conditions are reported in Table S1.
Real-Time PCR analysis
Real-Time PCR analysis was performed by TaqMan
approach in aiCycler iQ™ Real-Time PCR DetectionSystem
(Applied Biosystems, Carlsbad, CA, USA). Each sample was
analyzed in triplicate. Sets of primers and fluorogenic probes
specific for CA9, SNAI2, ESR1, IL6 and CD44 mRNAs were
purchased from Applied Biosystems. The reactions were
incubated at 50° for 2 min; 95°C for 15 min followed by 45
cycles of 95°C for 15 s and 60°C for 1 min. The relative amount
of the target mRNA was calculated equal to 2 − (ΔCt target mRNA- ΔCt
control), using human beta-glucuronidase mRNA as control,
except for mRNA immunoprecipitation assay, mRNA stability
assay, and cytoplasmic fractionation assay.
High Throughput Gene Expression Measurement with
Real Time PCR in a Microfluidic Dynamic Array
(Fluidigm® Real-Time PCR)
RNA was isolated using the PerfectPure RNA Cultured Cell
Kit with DNAse-1 digestion (5 Prime, Hamburg, Germany).
cDNA was synthesized using the SuperScriptII first-strand
synthesis kit (Invitrogen, Carlsbad, CA). For qPCR of pre-
mRNA and mRNA, respectively, forward primers were
positioned in the second intron and exon, and a shared reverse
primer (here called universal) was positioned in the third
constitutive exon. For genes in which universal primers
sequences were not available, 2 couples of primers were
designed in order to amplify respectively intronic and exonic
sequences. Each cDNA sample was mixed with the pool of
primers for a pre-amplification reaction of 14 cycles with
Reagent (Fluidigm PN 85000735) and TaqMan PreAmp Master
Mix, according to the manufacturer’s instructions. The
Preamplified cDNA was diluted 1:100. The modified 2x
TaqMan universal Master Mix was added to the diluted cDNA
in order to obtain a final concentration of Master Mix 1x in the
samples. The chip was primed in the NanoFlexTM 4-IFC
Controller prior to loading the samples and assay reagents into
the inlets. Data were analyzed by using Ct values and ΔΔCt
values. Each sample was in triplicates and normalized either
on GAPDH, B2M and TBP. Primer sequences are listed in
Table S2.
Western Blot and co-immunoprecipitation assay
Total proteins were extracted with RIPA Buffer (25mM Tris-
HCl, pH 7.6, 145 mM NaCl, 1% NP-40, SDS 0.1%, Na-
Deoxycolate 0.5%) added with Protease Inhibitor Cocktail
(Roche, Basel, Switzerland). Western blot analysis was
performed using the following antibodies: Laminin, Beta-
tubulin, anti-beta-catenin (E5), anti-Actin (C4) purchased from
Santa Cruz Biotechnology, (Santa Cruz, CA); anti-HuR
(Molecular probes, Invitrogen) purchased from molecular
probes; anti-CA9 (AF2188) purchased from R&D (Minneapolis,
MN) and clone M75 kindly provided by Prof J. Pastorek (Slovak
academy of Science (Bratislava, Czech Republic). Co-
immunoprecipitation assay was performed in CO-IP buffer
(50mM tris-HCl pH 7.5, 150 mM NaCl, 5mM EDTA, 1% NP40)
added with protease inhibitors (Roche).
mRNA immunoprecipitation assay
mRNA immunoprecipitation assay was performed following
standard protocol which preserves mRNA/protein interaction
using the Polysome lysis buffer [37]. In brief, cultured cells
were suspended in lysis buffer (100mM KCl, 5mM MgCl2,
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10mM Hepes, pH 7.0, 0.5% Nonidet P-40) supplemented with
RNase and protease inhibitors. Proteins were
immunoprecipitated using protein A beads (Santa Cruz) and
either anti-Beta-catenin (E5, Santa Cruz) or anti-HuR
(Molecular probes), or normal IgG (sc-2025, Santa Cruz)
mouse antibodies, in NT-2 buffer (50mM Tris, pH 7.4, 150mM
NaCl, 1mM MgCl2, 0.05% Nonidet P-40), supplemented with
RNAase inhibitor (40U/ul), DTT (1mM). Immunoprecipitates
were lysed in Trizol® reagent (Life technologies). cDNAs were
analyzed by RT-PCR (MCF7 cells, MDA-MB-468 and MDA-
MB-231 cells) or by Real Time PCR (T-MS). Data are
presented as fold increase of each mRNA bound to the specific
antibody over the control IgG [37].
Actinomycin D mRNA stability assay
Stability assay for mRNA was performed by exposing cells to
Actinomycin D at 100ng/ml and assessing level of each specific
mRNA at different time points (0 to 6 h): mRNA level at first
hour after Actinomycin exposure was taken as reference point
(time 0).
Cytoplasmic pre-ribosome and 40S ribosome
fractionation procedure
For isolations of ribosomal fractions two 10-cm plates of 80%
confluent cells were lysed in lysis buffer (10 mM NaCl, 3 mM
MgCl2, 20 mM Tris-HCl pH 7.5). Organelle-free cytoplasm was
obtained by saving supernatants after centrifugation at 14000 ×
g for 5 min at 4°C. Ribosomal fractions were then separated by
centrifugation of cytoplasmic lysate at 100.000 g (36.000 rpm)
in a SW41Ti rotor (Beckman) onto a 15-50% sucrose gradient
added with RNase inhibitor and cycloheximide. Fractions
corresponding to 40S ribosome subunit or low-density pre-
ribosomal cytoplasm were used for RNA and protein extraction
(Material S1A-B). RNA extraction was performed by TRI-
Reagent (Ambion). Proteins were extracted with TCA at 4°C,
dried at 95°C, and re-suspended in 1X Laemli buffer. mRNA
were assessed by Real Time PCR. Data are presented as fold
increase of each mRNA in beta-catenin knockdown cells over
controls.
Cytofluorimetric analysis
Cells were washed once with phosphate-buffered saline
(PBS) and then harvested with Cell Dissociation Solution Non-
enzymatic 1x (Sigma). Detached cells were washed with PBS
containing 5% FCS and 0.1% sodium azide (wash buffer) and
re-suspended at the concentration of 0.5*106 cells/100μl of
wash buffer. Combinations of fluorochrome-conjugated
monoclonal antibodies obtained from BD Bioscience
Pharmigen (San Diego, CA, USA) against human CD44
(G44-26, APC; cat. #560890) and CD24 (PE-cy7; cat. #
561646) or their respective isotype controls were added to the
cell suspension at concentrations recommended by the
manufacturer and incubated at 4°C in the dark for 30 min. The
labeled cells were washed in the wash buffer and then
analyzed on a LSR II Flow Cytometer (BD Biosciences).
Foci-forming assay
To test the ability of selected cell lines to form foci, cells were
plated into six-well-plates, maintained at confluence, replacing
the medium each 3-4 days. Foci were scored at day 14th.
Xenograft assay and tissue immunohistochemistry
2*106 MDA-M6B-468 cells were injected in the mammary fat-
pad of female nude mice. Tumor growth was monitored weekly
and then removed after 10 weeks (Weizmann Institute Animal
Care and Use Committee approved the animal experiment,
IACUC n. 01990412-2). 1*106 MDA-MB-231 cells were
subcutaneously injected in the flank of nude mice. Tumor
growth was monitored weekly and then removed after 4 weeks.
(Animal Ethical Committee of University of Bologna approved
the animal experiment, prot. n. 8134-X/10). Formalin-Fixed/
Paraffine embedded tissues were stained with Hematoxylin-
Eosin, and assessed by immunonistochemistry, with the
following antibodies: anti-ESR1 (clone ID5, DakoCytomation,
Glostrub, Denmark); anti-CDH1 (clone NCH38, Dako
Cytomation), anti-SNAI2 (L40C6, Cell Signalling, Beverly, MA),
anti-CA9 (clone M-75, kindly provided by J. Pastorek, Slovak
Academy of Sciences, Bratislava).
Statistics and bioinformatics
Bioinformatics analysis on AU-Rich element-containing
mRNA was performed consulting the online database AREsite
[38] (http://rna.tbi.univie.ac.at/cgi-bin/AREsite.cgi). Statistical
analysis was performed using SPSS software. Data are
presented as mean +/- s.d.; p values referring to t test are
reported, unless otherwise specified (n=3).
Results
Hypoxia elicits breast cancer cell dedifferentiation and
survival/proliferation by triggering CA9 and SNAI2
expression
In vitro, breast cancer stem/progenitor features are over-
represented in mammospheres (MS) [39]. Our investigation
was prompted by the observation that exposure or pre-
exposure to hypoxia (1%pO2) increased the MS forming ability
of MCF7 cells (Figure 1A), and of ductal breast carcinoma
tissues-derived cells (T-MS, Figure 1B). We then observed that
in MCF7 cells, as well as in T-MS, hypoxia increased the
mRNA expression of two crucial breast cancer stem cell
regulatory genes, namely carbonic anhydrase 9 (CA9) and
SNAI2 (Figure 1C), via de novo mRNA production (Figure
S1A). Importantly, SNAI2 shRNA knockdown reduced
normoxic MS forming capability, as well as blunted hypoxia MS
expansion (Figure 1D). Consistently, siRNA-mediated SNAI2
knockdown tampered hypoxic T-MS formation (Figure S1B).
Moreover, shRNA-mediated SNAI2 knockdown halted the
hypoxia-induced down-regulation of the epithelial differentiation
markers estrogen receptor alpha (ESR1), keratin 18 (KRT18)
and e-cadherin (CDH1) (Figure 1E and Figure S1C) and the
hypoxia-induced up-regulation of CD44 expression (Figure 1F),
a marker of breast cancer stem/progenitor cells [21,40]. Finally,
in line with the pro-survival/proliferative role of CA9 [21,22],
Beta-Catenin Post-Transcriptional Role in Stemness
PLOS ONE | www.plosone.org 4 November 2013 | Volume 8 | Issue 11 | e80742
siRNA-mediated CA9 silencing increased cell death and
hindered MS formation in hypoxic MCF7 cells (Figure 1G).
These data show that hypoxia induces a SNAI2-dependent de-
differentiation program and a CA9-dependent survival/
proliferation program, leading to an increase in the stem/
progenitor cells sub-population (Figure 1H).
Beta-catenin increases the breast cancer stem cell
phenotype in response to hypoxia independently of its
nuclear transcriptional activity
We then investigated the role of beta-catenin in the
regulation of the CA9 and SNAI2-dependent breast cancer
stem cell phenotype. MCF7 cells carrying beta-catenin specific
shRNA retroviral vector (shBeta) displayed a dramatic
reduction of SNAI2 and CA9 protein expression (Figure 2A),
coupled with reduced normoxic MS formation and impaired
hypoxic MS expansion (Figure 2B). Breast cancer stem/
progenitor cells are also over-represented in the CD44high/
CD24low sub-population [40]. Consistent with the data on MS,
MCF7-shBeta cells disclosed curtailed proportion of CD44high/
CD24low cells in normoxia, and blunted CD44high/CD24low
population expansion under hypoxia (Figure 2C). In long-term
hypoxia-exposed MCF7-shBeta cells, we also observed
decreased ability to form foci (Figure S2A). Moreover shRNA
mediated beta-catenin knockdown remarkably reduced soft
agar colony formation capability (Figure S3A), this latter being
a stringent in vitro assay for detecting cell malignant
transformation. These data led us to reason that beta-catenin
knockdown hampers stem/progenitor cell self-renewal.
Interestingly, beta-catenin knockdown also hindered the
hypoxia-induced down-regulation of ESR1 (Figure 2D),
revealing the capability of beta-catenin to play a pivotal role in
the hypoxia-induced de-differentiation program that parallels
the gain of stem cell features in breast cancer cells. We then
observed that hypoxia elicited substantial delocalization of
beta-catenin from the cell membrane to the cytoplasm, this fact
being paralleled by a reduction in cell-to-cell contacts (Figure
2E). Interestingly, hypoxia triggered neither beta-catenin
nuclear localization nor beta-catenin/TCF transcriptional activity
in MCF7 cells and in T-MS (Figure 2F, G). These data led us to
conceive that beta-catenin facilitates CA9 and SNAI2
expression and the ensuing stem cell phenotype in hypoxia-
exposed breast cancer cells, independently of its nuclear
transcriptional activity.
Hypoxia induces CA9 and SNAI2 expression via HIF1-
alpha dependent mRNA transcription and beta-catenin
dependent mRNA stabilization
CA9 and SNAI2 are hypoxia-inducible-factor-1-alpha
(HIF-1alpha) transcriptional targets [8,20]. Recently, it has
been suggested that beta-catenin promotes CA9 expression,
by acting as HIF-1alpha transcriptional co-factor in colon
cancer cells [8]. Prompted by these data, we sought to
investigate the effect of beta-catenin on HIF-1alpha-dependent
transcription, as well as on CA9 and SNAI2 promoter activity.
Surprisingly, the luciferase driven responsive reporter assay
demonstrated that beta-catenin over-expression hampers
HIF1-alpha transcriptional activity upon hypoxia exposure or
following HIF1-alpha transient overexpression (Figure 3A).
Consistently, beta-catenin knockdown triggered HIF1-alpha
transcriptional activity (Figure 3B). Similarly, beta-catenin
suppressed the hypoxia-induced CA9 and SNAI2 genes
promoter activity (Figure 3C). These findings point to the onset
of antagonistic activity between beta-catenin and HIF1-alpha
mediated transcription in hypoxia-exposed breast cancer cells.
In line with these results, the transfection of the dominant
negative isoform of TCF4 (TCF4-DN), which halts beta-catenin
transcriptional activity [6], was not able to decrease CA9 and
SNAI2 mRNA expression in hypoxia-exposed MCF7 cells
(Figure S3B). Evidence that beta-catenin paradoxically reduces
CA9 and SNAI2 promoter activity, but increases the expression
levels of cognate mRNA, prompted us to investigate mRNA
stability as a new layer of beta-catenin-dependent function. To
prove this hypothesis, we used actinomycin D, an inhibitor of
Polymerase 2 (Pol2) that impairs de novo mRNA transcription.
In line with our hypothesis, stable beta-catenin silencing
shortened CA9 and SNAI2 mRNA half-life in hypoxia exposed
MCF7 cells (Figure 3D). These data suggest that the hypoxia-
induced de-differentiation/stem cell program in breast cancer
cells relies upon the HIF1alpha-dependent production of CA9
and SNAI2 mRNA, followed by the beta-catenin dependent
stabilization of these mRNAs (Figure 3E).
Constitutively active beta-catenin post-transcriptional
activity in basal-like/triple-negative breast cancer cells
When we compared MCF7 derived MS to cognate adherent
cells for CA9 and SNAI2 expression, we found higher CA9 and
SNAI2 promoter activity and mRNA expression that was halted
in shBeta normoxic MS (Figure 4A-B). Albeit the phenomenon
was paralleled by the increase in beta-catenin cytoplasmic
localization (Figure 4C), similar levels of total beta-catenin
protein and transcriptional activity were present in adherent
and MCF7 derived MS (Figure 4D). These data point out that
the post-transcriptional activity of beta-catenin might be
involved in the maintenance of the stem/progenitor cell status,
even in normoxia. Following this reasoning, we drew our
attention to literature supporting the notion that cancer stem
cell features are overtly represented in basal-like breast cancer
cells and tissues [27,28]. Interestingly, in this aggressive tumor
subtype, cytoplasmic beta-catenin localization has recently
been observed [29–31]. Therefore, we sought to analyze the
functional relationship between beta-catenin post-
transcriptional activity and the cancer stem cell phenotype in
MDA-MB-468 and MDA-MB-231 basal-like breast cancer cell
lines [35]. In these cells we first observed the constitutive
cytoplasmic beta-catenin localization in normoxia (Figure 5A).
Then, in keeping with expectations, we found that the shRNA
mediated beta-catenin knockdown remarkably reduced the
extent of CD44high/CD24low stem/progenitor cell population
(Figure 5B). Moreover, we observed that MDA-MB-468-shBeta
xenografts were characterized by reduced growth rate and by
the presence of eosinofilic necrotic areas enriched with cells
showing hyper-chromatic and pleomorphic picnotic nuclei
(Figure 5C). In line with these features, beta-catenin
knockdown reduced CA9 and SNAI2 protein expression
(Figure 5D) and mRNA stability (Figure 5E). With regard to this
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Figure 1.  Hypoxia exposure induces breast cancer cell dedifferentiation and survival by triggering CA9 and SNAI2
expression.  A, Mammosphere (MS) formation assay in MCF7 cells in response to hypoxia exposure (1%pO2) or after pre-
exposure of adherent cells to 1%pO2 (Pre-1%pO2); MS forming capability of MCF7 cells in normoxia (Nor) is reported as basal
value; B, Tumor MS formation assay (T-MS) in Nor/1%pO2 ductal breast carcinoma tissues-derived cells, n=5; representative
pictures included; C, CA9 and SNAI2 mRNA in Nor/1%pO2 MCF7 cells and T-MS; D, MS formation assay of Ctrl/SNAI2-specific
shRNA retroviral vector (shSNAI2)-transfected MCF7 cells exposed to Nor/1%pO2; E, Real-Time PCR analysis of ESR1 and KRT18
mRNA levels in Ctrl/shSNAI2 MCF7 cells exposed to Nor/1%pO2; F, Real-Time PCR analysis of CD44 mRNA levels in Ctrl/shSNAI2
MCF7 cells exposed to Nor/1%pO2; G, Cell death and MS assay in scramble (Ctrl) and CA9 siRNA (siCA9) transfected MCF7 cells
exposed to Nor/1%pO2; H, Schematic representation of the role of CA9 and SNAI2 in the regulation of cancer stem cell features in
response to the hypoxic microenvironment. Data are presented as mean +/- s.d.; p values refers to t test. n=3, unless otherwise
specified.
doi: 10.1371/journal.pone.0080742.g001
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Figure 2.  Beta-catenin enhances the breast cancer stem cell phenotype in response to hypoxia independently of its
nuclear transcriptional activity.  A, Western analysis (WB) of beta-catenin, SNAI2 and CA9 protein levels in Ctrl/shBeta MCF7
cells upon Nor/1%pO2 conditions; B, MS forming assay in stable beta-catenin silenced (shBeta) MCF7 cells upon Nor/1%pO2
conditions; C, Cytofluorimetric analysis of CD44high/CD24low stem/progenitor population in ctrl/shBeta MCF7 cells upon Nor/1%pO2
conditions; D, Real-Time PCR analysis of ESR1 mRNA level in Ctrl/shBeta MCF7 cells upon Nor/1%pO2 conditions; E,
Immunofluorescence (IF) analysis of Beta-catenin in Nor/1%pO2 MCF7 cells; F, WB analysis of beta-catenin in Nor/1%pO2 MCF7
cells cytoplasmic and nuclear fractions (lamin B and beta-tubulin were used as fractionation controls); G, beta-catenin/TCF
transcriptional reporter (TOPFLASH) assay in MCF7 cells and T-MS under Nor/1%pO2. Data are presented as mean +/- s.d.; p
values refers to t test. n=3, unless otherwise specified.
doi: 10.1371/journal.pone.0080742.g002
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Figure 3.  Hypoxia induces CA9 and SNAI2 expression via HIF1-alpha dependent mRNA production and beta-catenin
dependent stabilization.  A, HIF-1alpha transcriptional reporter (HRE-Luc) assay in MCF7 cells transfected with wild type beta-
catenin (Beta-wt) under Nor/1%pO2 conditions or in combination with HIF1-alpha (HIF1a) encoding vector; B, HRE-Luc assay in
1%pO2-exposed ctrl/shBeta MCF7 cells; C, CA9-Luc and SNAI2-Luc assay in ctrl/Beta-wt transfected and in ctrl/shBeta MCF7 cells
under Nor/1%pO2 conditions; D, CA9 and SNAI2 mRNA stability assay following inhibition of Polymerase 2 transcriptional activity by
actinomycin D (100ng/ml) in ctrl/shBeta MCF7 cells exposed to 1%pO2; E, Schematic representation of the HIF1-alpha/beta-catenin
interplay in breast cancer cells in response to hypoxia: HIF1-alpha promotes transcription and cytoplasmic beta-catenin enhances
stabilization of SNAI2 and CA9 mRNAs; the negative effect of beta-catenin on HIF-1alpha-induced transcription is also depicted.
Data are presented as mean +/- s.d.; p values refers to t test. n=3, unless otherwise specified.
doi: 10.1371/journal.pone.0080742.g003
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issue, overtly blunted tumor growth rate was found in MDA-
MB-231 SNAI2-shRNA cells (Figure 5F). SNAI2 knockdown
xenografts disclosed the increase in epithelia-like cell
morphology and the re-expression of the breast tissue
differentiation markers ER-alpha and E-cadherin (Figure 5G).
Since that CA9 knockdown halts MDA-MB-231 xenografts [22],
the available data agree on the crucial role of the beta-catenin-
dependent CA9 and SNAI2 mRNA stability and expression in
the biology of basal-like/triple-negative breast cancer.
Beta-catenin binds and stabilizes CA9 and SNAI2
mRNAs 3’-UTR and facilitates the shift of HuR/mRNA
complexes to the 40S ribosome subunit
We then aimed at analyzing the molecular mechanism
through which beta-catenin exerts its post-transcriptional
control on CA9 and SNAI2 mRNAs. Cytoplasmic beta-catenin
has recently been reported to affect the stability of
cyclooxygenase-2 (COX2) mRNA by binding the mRNA 3’ un-
translated regions (3’-UTRs), in co-operation with the mRNA
binding protein HuR [14,15,17].
To evaluate whether the beta-catenin dependent increase in
CA9 and SNAI2 mRNA stability relies on their 3’-UTRs, we
examined luciferase encoding vectors carrying either CA9 or
SNAI2 3’UTR sequences inserted between the luciferase
coding sequence and the poly-adenylation site. Following this
approach, we observed hypoxia-induced increase in the CA9
and SNAI2 3’UTR luciferase reporters activity, which was
significantly reduced in normoxic and hypoxic MCF7-shBeta
cells, compared to controls (Figure 6A). These data indicate
that beta-catenin promotes CA9 and SNAI2 mRNA stability via
their 3’UTR sequences and that this phenomenon was
triggered by hypoxia. These findings were then confirmed in
normoxic basal-like cells, in which we observed the reduction
of CA9 and SNAI2 luciferase 3’UTR reporter activity in shBeta
Figure 4.  Beta-catenin maintains the stem/progenitor cell pool in normoxia, independently of its nuclear transcriptional
activity.  A, CA9 and SNAI2 Real Time PCR analysis and CA9-luc and SNAI2-Luc promoter activity in adherent MCF7 cells and
MCF7-MS; B, WB analysis of SNAI2 and CA9 in MCF7-MS; C, beta-catenin IF analysis in adherent MCF7 cells and MCF7-MS; D,
TOPFLASH assay and WB analysis of beta-catenin in adherent MCF7 cells and MCF7-MS. Data are presented as mean +/- s.d.; p
values refers to t test. n=3, unless otherwise specified.
doi: 10.1371/journal.pone.0080742.g004
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Figure 5.  In normoxic basal-like breast cancer cells, cytoplasmic beta-catenin promotes stem cell features in vitro and
tumor growth in vivo via constitutive stabilization of CA9 and SNAI2 mRNAs.  A, Beta-catenin IF analysis in luminal MCF7
cells and in basal-like MDA-MB-468 and MDA-MB-231 cells; B, Cytofluorimetric analysis of the CD44high/CD24low population in ctrl/
shBeta MDA-MB-468 and MDA-MB-231 cells; C, Ctrl/shBeta MDA-MB-468 10-weeks mammary fat pad xenograft assay (n=5, each
group); representative pictures of xenograft tissues hematoxylin-eosin staining are include; D, WB analysis of CA9, SNAI2 and beta-
catenin protein levels in ctrl/shBeta normoxic MDA-MB-468 and MDA-MB-231 cells; E, CA9 and SNAI2 mRNA stability assay
following inhibition of Polymerase 2 transcriptional activity by actinomycin D (100ng/ml) in Ctrl/shBeta MDA-MB-468 and MDA-
MB-231 cells; F, Four weeks growth curve of ctrl/shSNAI2 MDA-MB-231 subcutaneous xenograft assay (n=6, each group); G,
Hematoxylin-eosin, ESR1 and CDH1 immunohistochemical stainings in xenograft tissue sections. Data are presented as mean +/-
s.d.; p values refers to t test. n=3, unless otherwise specified.
doi: 10.1371/journal.pone.0080742.g005
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cells (Figure 6B, S3C). Then, the mRNA immuno-precipitation
assay revealed that SNAI2 and CA9 mRNA were present in
beta-catenin immune-precipitates from hypoxic MCF7 cells,
normoxic MDA-MB-468 and MDA-MB-231 cells, and hypoxic T-
MS (Figure 6C, S3D). These data provide compelling evidence
for the direct binding of beta-catenin to SNAI2 and CA9
mRNAs. Interestingly, bioinformatics analysis showed that
SNAI2 and CA9 mRNA 3-UTR’s contain U/AU-rich sequences
(Figure S4A), which represent acknowledged HuR binding sites
[41–44]. In keeping with the expectations, SNAI2 and CA9
mRNA were amplified from HuR immune-precipitates (Figure
S4B). Moreover, the siRNA-mediated HuR knockdown blunted
the expression of CA9 and SNAI2 mRNAs (Figure S4C). These
data suggest that HuR is part of the beta-catenin post-
transcriptional machinery, which promotes CA9 and SNAI2
mRNAs stabilization.
HuR ensures timely engagement of mRNA with ribosomes, a
function which remains poorly characterized [42]. The analysis
of density gradient-separated cytosolic fractions of MCF7 cells
conveyed that the exposure to hypoxia elicited the
delocalization of beta-catenin to the cytoplasmic and 40S
ribosome compartments, and that the phenomenon was
substantially reduced in shBeta cells (Figure 6D). Intriguingly,
constitutive beta-catenin localization in the ribosomal
compartment was observed in normoxic basal-like cells (Figure
S5A-S5B). Because beta-catenin binds cytoplasmic mRNA and
localizes to the ribosomal compartment, we assessed whether
beta-catenin plays a role in the transport of CA9 and SNAI2
mRNA to these cytoplasmic structures. We found that beta-
catenin knockdown substantially reduced the localization of
CA9 mRNA to the 40S ribosomal compartment (Figure 6E),
albeit the phenomenon was not significant for SNAI2 mRNA
(Figure S5C). We then observed that beta-catenin up-regulated
HuR expression (Figure 6F), suggesting that beta-catenin
increases the stabilization of target mRNAs, by increasing HuR
levels. Moreover, beta-catenin knockdown hindered the
hypoxia-induced translocation of HuR to the 40S ribosome
compartment (Figure 6G). In line with these data, beta-catenin
shRNA reduced the constitutive localization of HuR to the 40S
ribosome compartment in basal-like cells (Figure S5D). Overall,
our data suggest that cytoplasmic beta-catenin post-
transcriptionally regulates CA9 and SNAI2 mRNAs in hypoxic
luminal and normoxic basal-like cells, either by direct binding
cytoplasmic mRNAs or by facilitating the shuttling of HuR/
mRNA complexes to the 40S ribosome sub-unit (Figure 6H).
Beta-catenin post-transcriptionally regulates a subset
of EGF-regulated mRNAs
A peculiar feature of basal-like/triple-negative tumors is the
over-expression of epidermal growth factor receptor (EGFR)
[45,46], a receptor which plays a pivotal role in cancer
development [47,48]. EGFR is capable of modulating beta-
catenin intracellular localization [49,50]. Both SNAI2 and CA9
are EGFR downstream targets [51–53]. We observed that the
stable over-expression of wild-type EGFR in MCF7 cells raised
the level of cytoplasmic beta-catenin levels, a phenomenon
further augmented by EGF administration (Figure S6A).
Moreover, wild-type EGFR overexpression triggered the beta-
catenin dependent up-regulation of CA9 and SNAI2 mRNA
expression (Figure S6B). Following these data, we extended
our observations to other genes, which might be involved in the
beta-catenin dependent post-transcriptional mechanism
described above. We went on to analyze the expression level
of 34 EGF-induced mRNAs via high throughput Fluidigm
System (Table S1). In order to discriminate between
transcriptional and post-transcriptional targets of beta-catenin,
each gene was measured for its precursor mRNA (pre-mRNA)
and its mature mRNA expression levels, via amplification of
intronic and exonic sequences [54]. In line with our predictions,
no significant down-regulation of pre-mRNA level occurred in
shBeta basal-like cells (Figure 7A-B), with the unique exception
of IL8, which had been already described as a beta-catenin
transcriptional target [55]. We identified genes that underwent
beta-catenin dependent stabilization: seventeen in MDA-
MB-468 and thirteen MDA-MB-231 cells. Two subsets were
identified: the first contained genes displaying reduced mature
mRNA levels, coupled with unchanged or increased levels of
pre-mRNA; the second contained genes characterized by
unchanged mature mRNA levels and increased pre-mRNA
levels. Incidentally, the increase of certain pre-mRNA led to
hypothesize the existence of transcriptional compensatory
mechanisms, consequent to reduced mRNA stability,
reminiscent of the increase in CA9 and SNAI2 promoter
reporter activity observed in shBeta cells (see Figure 3B).
Striking overlapping of beta-catenin regulated genes was
observed between the two cell lines. In order to validate the
Fluidigm data, we focused our attention on the pivotal breast
cancer stem cells growth factor Interleukin 6 (IL6) [21,34]. We
were able to ascertain that beta-catenin knockdown reduced
IL6 mRNA stability in hypoxic MCF7 cells and normoxic MDA-
MB-468 cells (Figure 7C). As with CA9 and SNAI2, we found
that beta-catenin was bound to IL6 mRNA in hypoxic luminal
and normoxic basal-like cells (Figure 7D), and facilitated the
shuttling of IL6 mRNA to the 40S ribosomal compartment
(Figure 7E). Furthermore, the expected compensatory increase
of IL6 promoter activity was observed in shBeta cells (Figure
7F). These data demonstrate that the increase in IL6 mRNA
level occurs independently of the beta-catenin transcriptional
activity. Finally, bio-informatics analysis revealed that IL6
mRNA 3-UTR’s sequence harbored U/AU-Rich sequences
(Figure S7A), and that HuR knockdown almost extinguished
IL6 gene expression (Figure S7B). Collectively, our data
suggest that beta-catenin post-transcriptionally promotes
mRNA stability of a large subset of EGFR-regulated genes,
which share in stem cell regulation and part of the basal-like/
triple-negative phenotype.
Discussion and Conclusions
Comprehension of the post-transcriptional mechanisms that
steers stem cell features and cancer malignancy represents
cutting edge cancer research. Recent studies described a new
role of beta-catenin in the post-transcriptional regulation of
several cytoplasmic mRNAs [13–17], in addition to its well-
established role in promoting specific gene expression [6].
Here we provide evidence that this still-poorly characterized
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Figure 6.  Beta-catenin stabilizes CA9 and SNAI2 mRNAs through direct binding and facilitating the shift of HuR/mRNA
complexes to the ribosomal compartment.  A, CA9 and SNAI2 3’UTR-luciferase reporter (CA9-3’UTR-Luc and SNAI2-3’UTR-
Luc) assay in ctrl/shBeta MCF7 cells exposed to Nor/1%pO2 conditions; B, CA9 and SNAI2 3’UTR-luciferase reporter assay in ctrl/
shBeta MDA-MB-468 cells; Schematic diagram of the CA9 or SNAI2 3’UTR luciferase encoding vectors carrying either CA9 or
SNAI2 3’UTR sequences inserted between the luciferase coding sequence and the polyadenylation site; C, Quantitative CA9 and
SNAI2 mRNA immunoprecipitation assay with mouse IgG/beta-catenin antibody in 1%pO2 MCF7 cells, MDA-MB-468 and MDA-
MB-231 cells; D, WB analysis of cytoplasm pre-ribosomal (PRF) and 40S ribosomal (40S) cytoplasmic fractions of ctrl/shBeta MCF7
upon exposure to Nor/1%pO2 conditions; total beta-catenin protein levels are reported in Figure 2A and S5A; E, Real-Time PCR
analysis of CA9 mRNA levels in PRF/40S cytoplasmic fractions of 1%pO2 exposed ctrl/shBeta MCF7, MDA-MB-468 and MDA-
MB-231 cells; F, WB of beta-catenin and HuR protein levels in ctrl/beta-wt and in ctrl/shBeta MCF7 cells; G, WB analysis of HuR in
PRF and 40S cytoplasmic fractions of ctrl/shBeta MCF7 cells exposed to Nor/1%pO2; note that total HuR protein levels of Nor/
1%pO2 MCF7 cells refer to Figure S5D; H, Schematic representation of the cytoplasmic beta-catenin/HuR post-transcriptional
machinery in the regulation of CA9 and SNAI2 mRNAs, via stabilization, direct binding and shuttling to the ribosomal compartment.
Data are presented as mean +/- s.d.; p values refers to t test. n=3, unless otherwise specified.
doi: 10.1371/journal.pone.0080742.g006
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Figure 7.  Involvement of the beta-catenin-driven machinery in the stabilization of EGF-induced mRNAs.  A, B, Fluidigm®
Real-Time PCR analysis of EGFR pathway in ctrl/shBeta MDA-MB-468 and MDA-MB-231 cells. The assay distinguishes mature-
mRNA and immature (pre-mRNA) levels; C, IL6 mRNA stability assay following Polymerase 2 transcriptional activity inhibition by
actinomycin D (100ng/ml) in 1%pO2 exposed ctrl/shBeta MCF7 and MDA-MB-468 cells; D, Quantitative IL6 mRNA
immunoprecipitation assay with mouse IgG/beta-catenin antibody in 1%pO2 T-MS (Real-Time PCR) and normoxic MDA-MB-468
cells (Standard RT-PCR); E, Real-Time PCR of IL6 mRNA levels in PRF and 40S cytoplasmic fractions in Nor/1%pO2 MCF7, MDA-
MB-468 and MDA-MB-231 cells; F, IL6 promoter-driven luciferase (IL6-Luc) assay in Ctrl, Beta-wt and 1%pO2 exposed shBeta
MCF7 cells. Data are presented as mean +/- s.d.; p values refers to t test. n=3, unless otherwise specified.
doi: 10.1371/journal.pone.0080742.g007
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beta-catenin activity impacts the breast cancer stem cell
phenotype upon exposure to hypoxia. In particular, our study
demonstrates that, in response to hypoxia, the beta-
catenin/HuR post-transcriptional machinery reduces the
differentiation and boosts cancer stem cell features via
increased mRNA stabilization of the stem cell regulator SNAI2
and the hypoxia survival CA9 gene.
At the transcriptional level, our data support the notion that
hypoxia and its mediator HIF-1alpha do not cooperate with
beta-catenin transcriptional activity. These data are in line with
previous observations in colon and lung cancer cells [8,56], but
nevertheless in contrast to observations in embryonic stem
cells [9]. In particular, beta-catenin even represses HIF-1alpha
transcriptional activity, and the hypoxic transcriptional up-
regulation of the HIF-1alpha targets CA9 and SNAI2. Based on
the reasoning above, our data suggest that the expression of
breast cancer stem cell regulatory genes requires HIF-1-alpha
dependent mRNA production, followed by beta-catenin
dependent stabilization of the same mRNAs. The reciprocal
transcriptional inhibition between beta-catenin and HIF1-alpha
may take part in the negative feedback loop, which finely tunes
transcriptional and post-transcriptional mechanisms.
Cytoplasmic beta-catenin stabilizes Cox-2 mRNA through
physical interaction with its 3’-UTRs [14,15,17]. In line with
these findings, we demonstrated that beta-catenin binds and
stabilizes CA9, SNAI2 and IL6 mRNAs via their 3’-UTR
sequences. We also show that, at least for CA9 and IL6
mRNA, beta-catenin facilitates the shift to the 40S ribosomal
compartment. The interaction between beta-catenin and
cytoplasmic mRNA involves also HuR [14,15,17], a protein that
binds and stabilizes U/AU-Rich mRNAs [41–44]. HuR
expression correlates with poor outcome in breast cancers [57].
Here we show that HuR directly binds with and promotes the
expression of CA9, SNAI2 and IL6 mRNAs. Physical
interaction between HuR and beta-catenin has been previously
reported [14,15,17]. In agreement with these reports, we
detected a minor fraction of beta-catenin in HuR immune-
precipitates (Figure S8A). In regard to this issue, we also report
that stable beta-catenin silencing reduces HuR protein levels
and its localization to the 40S ribosomal subunit, suggesting
that beta-catenin facilitates the shift of HuR/mRNA complexes
to the 40S ribosomal compartment. Enhanced mRNA stability,
coupled with reduced transcriptional activity, is likely to be an
appropriate strategy for maintaining specific gene expression
profiles under energy restrictive conditions, such as hypoxia.
Basal-like/triple-negative tumors are aggressive breast
cancers characterized by the expression of a stem cell gene
profile [27,28]. Interestingly, cytoplasmic beta-catenin
localization was specifically observed in basal-like tissues
[29,31]. Over-expression of CA9 and SNAI2 genes has been
associated with this breast cancer sub-type [19,32,33]. Here
we show that in basal-like/triple-negative breast cancer cells,
beta-catenin/HuR post-transcriptional machinery operates even
under normoxic conditions, promoting CA9 and SNAI2 gene
mRNA stability and expression. The knockdown of CA9 and
SNAI2 substantially slows down in vivo tumor growth of basal-
like/triple-negative breast cancer cells [22] (this investigation).
Speculatively, in basal-like cells, the trigger effect of hypoxia on
beta-catenin post-transcriptional machinery may be mimicked
by specific genetic alterations, e.g. EGFR over-expression
[45,46]. EGFR plays a pivotal role in cancer [47,48] and EGFR-
targeted agents are among the therapeutic agents being
actively investigated in clinical trials in patients with triple-
negative/basal-like breast cancers [46]. Activation of the EGFR
pathway modifies beta-catenin intracellular localization [49,50],
and controls the homeostasis of normal and malignant
mammary gland stem cells [58]. In that regard we observed
elevated cytoplasmic beta-catenin level in EGFR over-
expressing MCF7 cells (Figure S6A). Interestingly, we also
detected increased EGFR levels and increased beta-catenin
cytoplasmic localization in cells transfected with p53-
inactivating mini-protein (Figure S6C). Since p53 mutations are
very common in triple negative/basal-like breast cancer [59],
this observation suggests that p53 potentially may contribute to
the onset of the basal-like/stem phenotype in breast cancer
cells triggering beta-catenin post-transcriptional activity. We
also provide evidence that beta-catenin post-transcriptionally
enhances the expression of an array of EGFR-controlled
genes. This observation is in line with the previously reported
enrichment in AU-Rich unstable mRNAs among the EGFR
signaling pathway target mRNAs [51]. Interestingly, we
observed a beta-catenin dependent regulation of several pro-
inflammatory cytokines (IL6, IL8, CXCL1, CXCL14). In
particular, we here characterized the beta-catenin post-
transcriptionally regulation of IL6, In addition, IL8 mRNA
immuno-precipitation and stabilization by beta catenin in breast
cancer stem cells was recently reported by our group [60]. Both
IL6 and IL8 are crucial regulators of breast cancer stem cell
growth and survival [21,34,61] and are part of the cancer stem
cells pro-inflammatory phenotype [62,63]. Owing to the role of
HuR in the initiation and resolution of inflammation [64], our
study suggests that the beta-catenin/HuR post-transcriptional
machinery regulates the inflammatory phenotype of EGFR
over-expressing cancers, such as triple negative/basal-like
tumors [46].
The expression of CD44, the hallmark of breast cancer stem
cells, is transcriptionally promoted by hypoxia, via HIF-1alpha
activation [20,65]. Here we observed that the expression of
CD44 is also post-transcriptionally regulated by beta-catenin, in
similarity to CA9, SNAI2 and IL6. In particular, shBeta cells
show reduced CD44 mRNA stability (Figure S9A) and impaired
CD44 mRNA translocation to the 40S ribosome compartment
(Figure S9B). Interestingly, HuR, but not beta-catenin, binds
CD44 mRNA (Figure S9C), and HuR knockdown blunts the
expression of CD44 gene (Figure S9D). These data suggest
that beta-catenin dependent post-transcriptional regulation
occurs to a large set of genes, which harbor U/AU-Rich motifs
at their 3’UTR, and which cooperate in the set up of the stem
cell phenotype.
In conclusion, our study highlights the role of post-
transcriptional mechanisms in the regulation of cancer stem
cell features and cancer aggressiveness, and leads to reason
that interfering with the beta-catenin post-transcriptional activity
may be an innovative strategy to target breast cancer stem
cells and to treat aggressive basal-like breast cancer patients.
Beta-Catenin Post-Transcriptional Role in Stemness
PLOS ONE | www.plosone.org 14 November 2013 | Volume 8 | Issue 11 | e80742
Supporting Information
Figure S1.  Hypoxia reduces proliferation and
differentiation in MCF7 cells, and elicits Snai2 dependent
stem cell features in MCF7 cells and T-MS. A, SNAI2 and
CA9 promoter luciferase reporter (SNAI2-Luc and CA9-Luc)
assay in Nor/1%pO2 MCF7 cells and T-MS; B, T-MS formation
upon ctrl/SNAI2-specific siRNA(siSNAI2) transfection of breast
cancer primary cells exposed to 1%pO2; C, WB analysis of e-
cadherin protein level in SNAI2-specific shRNA retroviral vector
(shSNAI2) MCF7 cells upon Nor/1%pO2 conditions.
(TIF)
Figure S2.  beta-catenin knockdown reduces focus
forming capability in hypoxia-exposed MCF7 cells. A,
Focus assay in 1%pO2 long-term-exposed (2 weeks) ctrl/
shBeta MCF7 cells.
(TIF)
Figure S3.  beta-catenin role in breast cancer cell
proliferation, colony-forming ability in soft agar and in CA9
and Snai2 transcriptional and post-transcriptional
regulation. A, soft agar assay in ctrl/shBeta MDA-MB-231
cells; B, RT-PCR analysis of CA9 and SNAI2 mRNA level in
1%pO2-exposed MCF7 cells transfected with ctrl/TCF4DN; C,
SNAI2-3’UTR-Luc assay in ctrl/shBeta MDA-MB-231 cells; D,
quantitative CA9 and SNAI2 mRNA immunoprecipitation assay
by control IgG/anti-beta-catenin antibody.
(TIF)
Figure S4.  HuR binds and stabilizes CA9 and SNAI2
mRNAs in hypoxic luminal and normoxic basal-like breast
cancer cells. A, schematic representation of CA9 and SNAI2
mRNA 3’-UTRs HuR binding sites as predicted by bio-
informatics analysis; B, quantitative CA9 and SNAI2 mRNA
immunoprecipitation assay by control IgG/beta-catenin
antibody; C, Real Time PCR analysis of SNAI2 and CA9
mRNA levels in Ctrl siHuR-transfected/1%pO2-exposed MCF7
cells and normoxic MDA-MB-468 cells.
(TIF)
Figure S5.  beta-catenin knock-down reduces HuR
expression and localization to the ribosomal compartment.
A, WB analysis of beta-catenin protein levels in MCF7 cells
exposed to 1%pO2; B, WB analysis of beta- catenin protein
levels in PRF and 40S cytoplasmic fractions of ctrl/shBeta
MDA-MB-468 and MDA-MB-231 cells; C, Real Time PCR
analysis of SNAI2 mRNA levels in PRF/40S cytoplasmic
fractions of ctrl/shBeta 1%pO2 MCF7 and MDA-MB-231 cells;
D, WB analysis of HuR protein levels in total cell lysates and in
PRF/40S cytoplasmic fractions of ctrl/shBeta MDA-MB-468 and
MDA-MB-231 cells; note that actin protein levels of ctrl/shBeta
MDA-MB-468 cells refers to Figure 5D.
(TIF)
Figure S6.  EGFr overexpression and activation promotes
the cytoplasmic localization of beta-catenin and the beta-
catenin dependent increase in SNAI2 and CA9 mRNA
expression. A, IF analysis of beta-catenin in MCF7 cells
stably-transfected with empty (MCF7-ctrl) or wild-type EGFR
(MCF7-EGFr) vector, in presence/absence of EGF (10ng/ml;
24h); B, RT-PCR analysis of CA9 and SNAI2 mRNA
expression levels in MCF7-ctrl/MCF7-EGFR and in MCF7-
EGFR cells, transiently transduced with ctrl/shBeta encoding
vectors; C, IF analysis of beta-catenin in p53-dominant-
negative (p53D) stably transfected MCF7 cells; note that IF of
MCF7-ctrl cells refers to panel A; D, WB analysis of EGFR
protein levels in MCF7-ctrl/MCF7-p53D.
(TIF)
Figure S7.  HuR binds and stabilizes IL6 mRNA. A,
schematic representation of IL6 3’-UTR HuR binding sites as
predicted by bioinformatics analysis; B, RT-PCR analysis of IL6
mRNA levels in 1%pO2 MCF7 cells, transiently transfected with
Ctrl/siHuR; note that the loading control (28S ribosomal subunit
mRNA) of ctrl/siHuR 1%pO2 MCF7 cells refers to Figure S4C.
(TIF)
Figure S8.  Beta-catenin/HuR physically interacts. A, Co-
immunoprecipitation assay of beta-catenin and HuR proteins in
MCF7, MCF7-MS and MDA-MB-231 cells.
(TIF)
Figure S9.  Beta-catenin/HuR post-transcriptional
machinery stabilizes CD44 mRNA. A, CD44 mRNA stability
assay (actinomycin D, 100ng/ml) in ctrl/shBeta MDA-MB-468
and MDA-MB-231 cells; B, Real Time PCR analysis of CD44
mRNA levels in PRF/40S cytoplasmic fractions of ctrl/shBeta
1%pO2 MCF7, MDA-MB-468 and MDA-MB-231 cells; C,
quantitative CD44 mRNA immunoprecipitation assay with
control IgG/anti-HuR/anti-beta-catenin antibody in 1%pO2
MCF7 cells and MDA-MB-468 cells; D, RT-PCR analysis of
CD44 mRNA levels in scr/siHuR transfected MCF7 cells,
exposed to 1%pO2; note that the loading control (28S
ribosomal subunit mRNA) of ctrl/shBeta 1%pO2 MCF7 cells
refers to Figure S4C.
(TIF)
Material S1.  Cytoplasmic pre-ribosomal and ribosome
fractionation. A, profile of cytoplasmic fractions obtained after
centrifugation of cytoplasmic lysates; B, fractions
corresponding to low density pre-ribosomal cytoplasm (PRF),
40S, 60-80S and polysomes were pooled and examined in 1%
agarose gel and western blot to verify the presence of the
rRNA 18S, 28S and of the ribosomal protein S6, a component
of the 40S ribosomal subunit.
(TIF)
Table S1.  List of primer sequences and PCR conditions.
(DOC)
Table S2.  List of primer sequences used for Real Time
PCR in a Microfluidic Dynamic Array (Fluidigm® Real-Time
PCR).
Beta-Catenin Post-Transcriptional Role in Stemness
PLOS ONE | www.plosone.org 15 November 2013 | Volume 8 | Issue 11 | e80742
(DOC)
Acknowledgements
We are grateful to Marc Van De Wetering, Bert Vogelstein, Eric
Huang, Pier Paolo di Fiore, Jaromir Pastorek, Giovanni Melillo,
Togo Ikuta, Rolf Kemler and Rakesh Kumar for providing key
reagents.
Author Contributions
Conceived and designed the experiments: GD YY LM GS MB.
Performed the experiments: GD SB ML SDC AP LD CC GS.
Analyzed the data: GD GS. Contributed reagents/materials/
analysis tools: DS MT YY LM. Wrote the manuscript: GD GS
MB.
References
1. Keith B, Simon MC (2007) Hypoxia-inducible factors, stem cells, and
cancer. Cell 129: 465-472. doi:10.1016/j.cell.2007.04.019. PubMed:
17482542.
2. Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A (2010) Oxygen in
stem cell biology: a critical component of the stem cell niche. Cell Stem
Cell 7: 150-161. doi:10.1016/j.stem.2010.07.007. PubMed: 20682444.
3. Semenza GL (2012) Hypoxia-inducible factors: mediators of cancer
progression and targets for cancer therapy. Trends Pharmacol Sci 33:
207-214. doi:10.1016/j.tips.2012.01.005. PubMed: 22398146.
4. Harris AL (2002) Hypoxia--a key regulatory factor in tumour growth. Nat
Rev Cancer 2: 38-47. doi:10.1038/nrc704. PubMed: 11902584.
5. Axelson H, Fredlund E, Ovenberger M, Landberg G, Påhlman S (2005)
Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind
heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol
16: 554-563. doi:10.1016/j.semcdb.2005.03.007. PubMed: 16144692.
6. Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer.
Nature 434: 843-850. doi:10.1038/nature03319. PubMed: 15829953.
7. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M et al.
(2009) Regulation of mammary stem/progenitor cells by PTEN/Akt/
beta-catenin signaling. PLOS Biol 7: e1000121. PubMed: 19492080.
8. Kaidi A, Williams AC, Paraskeva C (2007) Interaction between beta-
catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol
9: 210-217. doi:10.1038/ncb1534. PubMed: 17220880.
9. Mazumdar J, O'Brien WT, Johnson RS, LaManna JC, Chavez JC et al.
(2010) O2 regulates stem cells through Wnt/beta-catenin signalling. Nat
Cell Biol 12: 1007-1013. doi:10.1038/ncb2102. PubMed: 20852629.
10. Gorospe M, Tominaga K, Wu X, Fahling M, Ivan M (2011) Post-
Transcriptional Control of the Hypoxic Response by RNA-Binding
Proteins and MicroRNAs. Front Mol Neurosci 4: 7. PubMed: 21747757.
11. Paulding WR, Czyzyk-Krzeska MF (2000) Hypoxia-induced regulation
of mRNA stability. Adv Exp Med Biol 475: 111-121. PubMed:
10849653.
12. Masuda K, Abdelmohsen K, Gorospe M (2009) RNA-binding proteins
implicated in the hypoxic response. J Cell Mol Med 13: 2759-2769. doi:
10.1111/j.1582-4934.2009.00842.x. PubMed: 19583805.
13. Briata P, Ilengo C, Corte G, Moroni C, Rosenfeld MG et al. (2003) The
Wnt/beta-catenin-->Pitx2 pathway controls the turnover of Pitx2 and
other unstable mRNAs. Mol Cell 12: 1201-1211. doi:10.1016/
S1097-2765(03)00407-6. PubMed: 14636578.
14. Lee HK, Jeong S (2006) Beta-Catenin stabilizes cyclooxygenase-2
mRNA by interacting with AU-rich elements of 3'-UTR. Nucleic Acids
Res 34: 5705-5714. doi:10.1093/nar/gkl698. PubMed: 17040897.
15. Lee HK, Kwak HY, Hur J, Kim IA, Yang JS et al. (2007) beta-catenin
regulates multiple steps of RNA metabolism as revealed by the RNA
aptamer in colon cancer cells. Cancer Res 67: 9315-9321. doi:
10.1158/0008-5472.CAN-07-1128. PubMed: 17909039.
16. Farina AK, Bong YS, Feltes CM, Byers SW (2009) Post-transcriptional
regulation of cadherin-11 expression by GSK-3 and beta-catenin in
prostate and breast cancer cells. PLOS ONE 4: e4797. doi:10.1371/
journal.pone.0004797. PubMed: 19274078.
17. Kim I, Kwak H, Lee HK, Hyun S, Jeong S (2012) beta-Catenin
recognizes a specific RNA motif in the cyclooxygenase-2 mRNA 3'-
UTR and interacts with HuR in colon cancer cells. Nucleic Acids Res
40: 6863-6872. doi:10.1093/nar/gks331. PubMed: 22544606.
18. Kaluz S, Kaluzova M, Liao SY, Lerman M, Stanbridge EJ (2009)
Transcriptional control of the tumor- and hypoxia-marker carbonic
anhydrase 9: A one transcription factor (HIF-1) show? Biochim Biophys
Acta 1795: 162-172.
19. Storci G, Sansone P, Trere D, Tavolari S, Taffurelli M et al. (2008) The
basal-like breast carcinoma phenotype is regulated by SLUG gene
expression. J Pathol 214: 25-37. doi:10.1002/path.2254. PubMed:
17973239.
20. Storci G, Sansone P, Mari S, D'Uva G, Tavolari S et al. (2010)
TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis,
which imparts breast cancer cells with a stem cell-like phenotype. J Cell
Physiol 225: 682-691. doi:10.1002/jcp.22264. PubMed: 20509143.
21. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C et al. (2007)
IL-6 triggers malignant features in mammospheres from human ductal
breast carcinoma and normal mammary gland. J Clin Invest 117:
3988-4002. doi:10.1172/JCI32533. PubMed: 18060036.
22. Lock FE, McDonald PC, Lou Y, Serrano I, Chafe SC et al. (2012)
Targeting carbonic anhydrase IX depletes breast cancer stem cells
within the hypoxic niche. Oncogene, 32: 5210–9. PubMed: 23208505.
23. Zatovicova M, Jelenska L, Hulikova A, Csaderova L, Ditte Z et al.
(2010) Carbonic anhydrase IX as an anticancer therapy target:
preclinical evaluation of internalizing monoclonal antibody directed to
catalytic domain. Curr Pharm Des 16: 3255-3263. doi:
10.2174/138161210793429832. PubMed: 20819068.
24. Pastorekova S, Zatovicova M, Pastorek J (2008) Cancer-associated
carbonic anhydrases and their inhibition. Curr Pharm Des 14: 685-698.
doi:10.2174/138161208783877893. PubMed: 18336315.
25. Proia TA, Keller PJ, Gupta PB, Klebba I, Jones AD et al. (2011)
Genetic predisposition directs breast cancer phenotype by dictating
progenitor cell fate. Cell Stem Cell 8: 149-163. doi:10.1016/j.stem.
2010.12.007. PubMed: 21295272.
26. Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V et al. (2012)
Slug and Sox9 cooperatively determine the mammary stem cell state.
Cell 148: 1015-1028. doi:10.1016/j.cell.2012.02.008. PubMed:
22385965.
27. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW et al. (2008) An
embryonic stem cell-like gene expression signature in poorly
differentiated aggressive human tumors. Nat Genet 40: 499-507. doi:
10.1038/ng.127. PubMed: 18443585.
28. Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK et al.
(2008) The CD44+/CD24- phenotype is enriched in basal-like breast
tumors. Breast Cancer Res 10: R53. doi:10.1186/bcr2051. PubMed:
18559090.
29. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI et al.
(2010) Wnt/beta-catenin pathway activation is enriched in basal-like
breast cancers and predicts poor outcome. Am J Pathol 176:
2911-2920. doi:10.2353/ajpath.2010.091125. PubMed: 20395444.
30. López-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P et al.
(2010) Cytoplasmic localization of beta-catenin is a marker of poor
outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev
19: 301-309. doi:10.1158/1055-9965.EPI-09-0741. PubMed: 20056651.
31. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB et al.
(2011) beta-Catenin pathway activation in breast cancer is associated
with triple-negative phenotype but not with CTNNB1 mutation. Mod
Pathol 24: 209-231. doi:10.1038/modpathol.2010.205. PubMed:
21076461.
32. Tan EY, Yan M, Campo L, Han C, Takano E et al. (2009) The key
hypoxia regulated gene CAIX is upregulated in basal-like breast
tumours and is associated with resistance to chemotherapy. Br J
Cancer 100: 405-411. doi:10.1038/sj.bjc.6604844. PubMed: 19165203.
33. Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno
G et al. (2008) Epithelial-mesenchymal transition in breast cancer
relates to the basal-like phenotype. Cancer Res 68: 989-997. doi:
10.1158/0008-5472.CAN-07-2017. PubMed: 18281472.
34. Korkaya H, Kim GI, Davis A, Malik F, Henry NL et al. (2012) Activation
of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in
HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population.
Mol Cell 47: 570-584. doi:10.1016/j.molcel.2012.06.014. PubMed:
22819326.
35. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL et al. (2006) A
collection of breast cancer cell lines for the study of functionally distinct
cancer subtypes. Cancer Cell 10: 515-527. doi:10.1016/j.ccr.
2006.10.008. PubMed: 17157791.
Beta-Catenin Post-Transcriptional Role in Stemness
PLOS ONE | www.plosone.org 16 November 2013 | Volume 8 | Issue 11 | e80742
36. Shaulian E, Zauberman A, Ginsberg D, Oren M (1992) Identification of
a minimal transforming domain of p53: negative dominance through
abrogation of sequence-specific DNA binding. Mol Cell Biol 12:
5581-5592. PubMed: 1448088.
37. Tenenbaum SA, Lager PJ, Carson CC, Keene JD (2002) Ribonomics:
identifying mRNA subsets in mRNP complexes using antibodies to
RNA-binding proteins and genomic arrays. Methods 26: 191-198. doi:
10.1016/S1046-2023(02)00022-1. PubMed: 12054896.
38. Gruber AR, Fallmann J, Kratochvill F, Kovarik P, Hofacker IL (2011)
AREsite: a database for the comprehensive investigation of AU-rich
elements. Nucleic Acids Res 39: D66-D69. doi:10.1093/nar/gkq990.
PubMed: 21071424.
39. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF et al.
(2003) In vitro propagation and transcriptional profiling of human
mammary stem/progenitor cells. Genes Dev 17: 1253-1270. doi:
10.1101/gad.1061803. PubMed: 12756227.
40. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF
(2003) Prospective identification of tumorigenic breast cancer cells.
Proc Natl Acad Sci U S A 100: 3983-3988. doi:10.1073/pnas.
0530291100. PubMed: 12629218.
41. López de Silanes I, Zhan M, Lal A, Yang X, Gorospe M (2004)
Identification of a target RNA motif for RNA-binding protein HuR. Proc
Natl Acad Sci U S A 101: 2987-2992. doi:10.1073/pnas.0306453101.
PubMed: 14981256.
42. Srikantan S, Gorospe M (2011) UneCLIPsing HuR nuclear function.
Mol Cell 43: 319-321. doi:10.1016/j.molcel.2011.07.016. PubMed:
21816340.
43. Mukherjee N, Corcoran DL, Nusbaum JD, Reid DW, Georgiev S et al.
(2011) Integrative regulatory mapping indicates that the RNA-binding
protein HuR couples pre-mRNA processing and mRNA stability. Mol
Cell 43: 327-339. doi:10.1016/j.molcel.2011.06.007. PubMed:
21723170.
44. Lebedeva S, Jens M, Theil K, Schwanhäusser B, Selbach M et al.
(2011) Transcriptome-wide analysis of regulatory interactions of the
RNA-binding protein HuR. Mol Cell 43: 340-352. doi:10.1016/j.molcel.
2011.06.008. PubMed: 21723171.
45. Cleator S, Heller W, Coombes RC (2007) Triple-negative breast
cancer: therapeutic options. Lancet Oncol 8: 235-244. doi:10.1016/
S1470-2045(07)70074-8. PubMed: 17329194.
46. Carey L, Winer E, Viale G, Cameron D, Gianni L (2010) Triple-negative
breast cancer: disease entity or title of convenience? Nat Rev Clin
Oncol 7: 683-692. doi:10.1038/nrclinonc.2010.154. PubMed:
20877296.
47. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling
network. Nat Rev Mol Cell Biol 2: 127-137. doi:10.1038/35052073.
PubMed: 11252954.
48. Yarden Y, Pines G (2012) The ERBB network: at last, cancer therapy
meets systems biology. Nat Rev Cancer 12: 553-563. doi:10.1038/
nrc3309. PubMed: 22785351.
49. Lu Z, Ghosh S, Wang Z, Hunter T (2003) Downregulation of caveolin-1
function by EGF leads to the loss of E-cadherin, increased
transcriptional activity of beta-catenin, and enhanced tumor cell
invasion. Cancer Cell 4: 499-515. doi:10.1016/
S1535-6108(03)00304-0. PubMed: 14706341.
50. Ji H, Wang J, Nika H, Hawke D, Keezer S et al. (2009) EGF-induced
ERK activation promotes CK2-mediated disassociation of alpha-
Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell
36: 547-559. doi:10.1016/j.molcel.2009.09.034. PubMed: 19941816.
51. Amit I, Citri A, Shay T, Lu Y, Katz M et al. (2007) A module of negative
feedback regulators defines growth factor signaling. Nat Genet 39:
503-512. doi:10.1038/ng1987. PubMed: 17322878.
52. Kusewitt DF, Choi C, Newkirk KM, Leroy P, Li Y et al. (2009) Slug/
Snai2 is a downstream mediator of epidermal growth factor receptor-
stimulated reepithelialization. J Invest Dermatol 129: 491-495. doi:
10.1038/jid.2008.222. PubMed: 18685621.
53. Li Y, Wang H, Tu C, Shiverick KT, Silverman DN et al. (2011) Role of
hypoxia and EGF on expression, activity, localization and
phosphorylation of carbonic anhydrase IX in MDA-MB-231 breast
cancer cells. Biochim Biophys Acta 1813: 159-167. doi:10.1016/
j.bbamcr.2010.09.018. PubMed: 20920536.
54. Zeisel A, Köstler WJ, Molotski N, Tsai JM, Krauthgamer R et al. (2011)
Coupled pre-mRNA and mRNA dynamics unveil operational strategies
underlying transcriptional responses to stimuli. Mol Syst Biol 7: 529.
PubMed: 21915116.
55. Lévy L, Neuveut C, Renard CA, Charneau P, Branchereau S et al.
(2002) Transcriptional activation of interleukin-8 by beta-catenin-Tcf4. J
Biol Chem 277: 42386-42393. doi:10.1074/jbc.M207418200. PubMed:
12200448.
56. Lim JH, Chun YS, Park JW (2008) Hypoxia-inducible factor-1alpha
obstructs a Wnt signaling pathway by inhibiting the hARD1-mediated
activation of beta-catenin. Cancer Res 68: 5177-5184. doi:
10.1158/0008-5472.CAN-07-6234. PubMed: 18593917.
57. Heinonen M, Bono P, Narko K, Chang SH, Lundin J et al. (2005)
Cytoplasmic HuR expression is a prognostic factor in invasive ductal
breast carcinoma. Cancer Res 65: 2157-2161. doi:
10.1158/0008-5472.CAN-04-3765. PubMed: 15781626.
58. Farnie G, Clarke RB, Spence K, Pinnock N, Brennan K et al. (2007)
Novel cell culture technique for primary ductal carcinoma in situ: role of
Notch and epidermal growth factor receptor signaling pathways. J Natl
Cancer Inst 99: 616-627. doi:10.1093/jnci/djk133. PubMed: 17440163.
59. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S et al. (2001) Gene
expression patterns of breast carcinomas distinguish tumor subclasses
with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
doi:10.1073/pnas.191367098. PubMed: 11553815.
60. Storci G, Bertoni S, De Carolis S, Papi A, Nati M et al. (2013) Slug/
beta-Catenin-Dependent Proinflammatory Phenotype in Hypoxic Breast
Cancer Stem Cells. Am J Pathol.
61. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M et al. (2010) CXCR1
blockade selectively targets human breast cancer stem cells in vitro
and in xenografts. J Clin Invest 120: 485-497. doi:10.1172/JCI39397.
PubMed: 20051626.
62. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:
860-867. doi:10.1038/nature01322. PubMed: 12490959.
63. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related
inflammation. Nature 454: 436-444. doi:10.1038/nature07205. PubMed:
18650914.
64. Anderson P (2010) Post-transcriptional regulons coordinate the
initiation and resolution of inflammation. Nat Rev Immunol 10: 24-35.
doi:10.1038/nri2685. PubMed: 20029446.
65. Krishnamachary B, Penet MF, Nimmagadda S, Mironchik Y, Raman V
et al. (2012) Hypoxia Regulates CD44 and Its Variant Isoforms through
HIF-1alpha in Triple Negative Breast Cancer. PLOS ONE 7: e44078.
doi:10.1371/journal.pone.0044078. PubMed: 22937154.
Beta-Catenin Post-Transcriptional Role in Stemness
PLOS ONE | www.plosone.org 17 November 2013 | Volume 8 | Issue 11 | e80742
